126 related articles for article (PubMed ID: 33073649)
1. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract][Full Text] [Related]
2. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.
Zhang X; Lv QL; Huang YT; Zhang LH; Zhou HH
J Exp Clin Cancer Res; 2017 Aug; 36(1):105. PubMed ID: 28784180
[TBL] [Abstract][Full Text] [Related]
3. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
4. A risk prediction model of DNA methylation improves prognosis evaluation and indicates gene targets in prostate cancer.
Zhang E; Hou X; Hou B; Zhang M; Song Y
Epigenomics; 2020 Feb; 12(4):333-352. PubMed ID: 32027524
[No Abstract] [Full Text] [Related]
5. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH.
Xiong YC; Wang J; Cheng Y; Zhang XY; Ye XQ
Mol Cell Biochem; 2020 May; 468(1-2):185-193. PubMed ID: 32200471
[TBL] [Abstract][Full Text] [Related]
6. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
Li X; Zhang W; Song J; Zhang X; Ran L; He Y
Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MYBL2 predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.
Le L; Luo J; Wu H; Chen L; Tang X; Fu F
Eur J Histochem; 2021 Mar; 65(2):. PubMed ID: 33782625
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
9. MTSS1 hypermethylation is associated with prostate cancer progression.
Chen J; Huang L; Zhu Q; Wang Z; Tang Z
J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
[TBL] [Abstract][Full Text] [Related]
10. Prognostic DNA methylation markers for prostate cancer.
Strand SH; Orntoft TF; Sorensen KD
Int J Mol Sci; 2014 Sep; 15(9):16544-76. PubMed ID: 25238417
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a prognostic four‑gene methylation signature associated with radiotherapy for head and neck squamous cell carcinoma.
Ma J; Li R; Wang J
Mol Med Rep; 2019 Jul; 20(1):622-632. PubMed ID: 31180552
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo.
Shukeir N; Stefanska B; Parashar S; Chik F; Arakelian A; Szyf M; Rabbani SA
Br J Pharmacol; 2015 Jun; 172(11):2769-81. PubMed ID: 25631332
[TBL] [Abstract][Full Text] [Related]
13. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
14. MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer.
Liang HB; Cao Y; Ma Q; Shu YJ; Wang Z; Zhang F; Ye YY; Li HF; Xiang SS; Song XL; Xu Y; Zhang YC; Bao RF; Yuan RY; Zhang YJ; Hu YP; Jiang L; Li ML; Wang XA; Wu XS; Wu WG; Zhao S; Fand Y; Cui XP; Lu YS; Zhou J; Zheng L; Gong W; Liu YB
Cell Physiol Biochem; 2017; 41(5):2117-2131. PubMed ID: 28427077
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
[TBL] [Abstract][Full Text] [Related]
16. Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma.
Shen S; Wang G; Shi Q; Zhang R; Zhao Y; Wei Y; Chen F; Christiani DC
Clin Epigenetics; 2017; 9():88. PubMed ID: 28852427
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of N-myc downstream regulated gene 1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation and invasion of prostate cancer cells.
Li Y; Pan P; Qiao P; Liu R
Int J Oncol; 2015 Sep; 47(3):1001-8. PubMed ID: 26202882
[TBL] [Abstract][Full Text] [Related]
18. HIC1 modulates prostate cancer progression by epigenetic modification.
Zheng J; Wang J; Sun X; Hao M; Ding T; Xiong D; Wang X; Zhu Y; Xiao G; Cheng G; Zhao M; Zhang J; Wang J
Clin Cancer Res; 2013 Mar; 19(6):1400-10. PubMed ID: 23340301
[TBL] [Abstract][Full Text] [Related]
19. Circ_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143.
Li M; Liu Y; Liu J; Li W; Li N; Xue D; Zhang X; Wang P
Aging (Albany NY); 2019 Nov; 11(22):10626-10643. PubMed ID: 31756170
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer.
Yin X; Kong L; Liu P
Clin Epigenetics; 2021 May; 13(1):109. PubMed ID: 33980289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
